GW Pharmaceuticals plc Reports Financial Results and Operational Progress for the Third Quarter Ended September 30, 2019
Epidiolex U.S. year to date net sales of $188.0 million, including Q3 net sales of $86.1 million.
Read More
Category: UK Stocks
GW Pharmaceuticals to Present at Upcoming Investor Conferences
Stephen Schultz, GW’s Vice President of Investor Relations, will present at two upcoming conferences.
Read More
GW Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference on Wednesday, October 2nd, 2019
GW Pharmaceuticals is the world leader in the development and commercialization of cannabinoid prescription medicines.
Read More
GW Pharmaceuticals receives European Commission approval for EPIDYOLEX® (cannabidiol) for the treatment of seizures in patients with two rare, severe forms of childhood-onset epilepsy
The approval paves the way for the launch of the medicine across Europe.
Read More
GW Pharmaceuticals to Present at the Morgan Stanley 17th Annual Global Healthcare Conference on Wednesday, September 11th, 2019
GW Pharmaceuticals is a world leader in the science, development, and commercialization of cannabinoid prescription medicines.
Read MoreGET LISTED
